Latest News

Gregory Lubiniecki, MD, of Merck Research Laboratories
First-Line Pembrolizumab Plus Olaparib Maintenance Misses Survival End Points in Metastatic Nonsquamous NSCLC

March 21st 2024

Pembrolizumab plus olaparib as first-line maintenance therapy did not improve survival in patients with metastatic nonsquamous non–small cell lung cancer.

Dana Walker, MD, of Bristol Myers Squibb
First-Line Nivolumab/Ipilimumab Combo Meets OS End Point in Advanced HCC

March 20th 2024

Michael J. Overman, MD, associate vice president, research, the MD Anderson Cancer Network; professor, the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, chair, the Division of Executive Committee, the Medical Staff, The University of Texas MD Anderson Cancer Center
Immunotherapy Success Signals Paradigm Shift Toward Nonoperative Management in Select GI Cancers

March 4th 2024

Discordant dMMR/IHC Status Correlates With Improved Treatment Outcomes in CRC and Endometrial Cancer
Discordant dMMR/IHC Status Correlates With Improved Treatment Outcomes in CRC and Endometrial Cancer

February 27th 2024

Paolo A. Ascierto, MD, of Istituto Nazionale Tumori IRCCS Fondazione Pascale
Long-Term CheckMate 238 Data Support Adjuvant Nivolumab Vs Ipilimumab in Resected Melanoma

February 13th 2024

Latest CME Events & Activities

What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations

View More

Expert Illustrations and Commentaries™: Evaluating the Potential for Novel Mechanistic Approaches to Overcome Clinical Gaps in the Care of Patients with LR-MDS

View More

Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond

View More

Medical Crossfire®: Expert Perspectives in Geographic Atrophy – How Can We Prepare for a New Era of Treatment?

View More

Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy

View More

Clinical Vignettes™: Integrating Novel CAR T-Cell Therapies Across Lymphoid Malignancies with an Eye Toward the Future of Care

View More

The Latest on Acute Lymphocytic Leukemia

View More

Updates in Myelodysplastic Syndromes

View More

A Focus on Acute Myeloid Leukemia

View More

Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes

View More

Community Practice Connections™: What’s Next for Patients with Breast Cancer, and How Can We Effectively Optimize PARP-, HER2/3-, and TROP2-Targeted Regimens in Treatment Plans?

View More

Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma

View More

Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer

View More

Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse

View More

Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs

View More

Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy

View More

Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma

View More

Go To PER in Chicago

May 31, 2024 - June 2, 2024

Register Now!

The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward

View More

Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment

View More

Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician

View More

Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC

View More

Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target

View More

Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?

View More

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure

View More

23rd Annual International Congress on the Future of Breast Cancer® East

July 19-20, 2024

Register Now!

Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies

View More

Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer

View More

Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer

View More

<1
...